The treatment, named AZD7442, is a combination tixagevimab and cilgavimab.
At primary analysis, none of the trial participants who contracted symptomatic COVID-19 had severe cases. More than 75 percent of participants had comorbidities, including conditions that cause a reduced immune response to vaccination.
“We need additional approaches for individuals who are not adequately protected by COVID-19 vaccines,” Sir Mene Pangalos, PhD, AstraZeneca’s executive vice president of biopharmaceuticals and research and development, said in a news release. “We are very encouraged by these efficacy and safety data in high-risk people, showing our long-acting antibody combination has the potential to protect from symptomatic and severe disease, alongside vaccines.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
